The value of a High-Volume Image-Guided Injection in chronic midportion Achilles tendinopathy: a double-blind, placebo-controlled, randomised clinical trial

Phase 4

Completed

• Conditions: Achilles tendinopathy; overuse injury Achilles tendon; 10043237

• Registration Number: NL-OMON47722
• Lead Sponsor: Haaglanden Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 84

Inclusion Criteria

- Age 18-70 years.
- Clinical diagnosis of chronic midportion Achilles tendinopathy: Painfull swelling of the Achilles tendon, 2-7 cm proximal to it*s calcaneal insertion.
- Non-response to excercise program for 6 weeks.
- Painfull Achilles tendon for more than 2 months.
- Neovascularisation is present on Power Doppler Ultrasonography examination

Exclusion Criteria

- Clinical suspicion of insertional disorders.
- Clinical suspicion of Achilles tendon rupture.
- Clinical suspicion of plantar flexor tenosynovitis.
- Clinical suspicion of peroneal tendinopathy or subluxation.
- Clicical suspicion of sural nerve pathology.
- Condition of the Achilles tendon caused by medication, such as quinolones and statins.
- Known to have the following disorders: spondylarthropathy, gout, hyperlipidemia, rheumatoid arthritis and sarcoïdosis.
- Inability to perform a heavy load eccentric exercise program.
- Recently prescribed drugs (within 2 years) with a putative effect on symptoms and tendon healing (quinolone antibiotics, corticosteroids).
- Presence of pregancy.
- Previous Achilles tendon rupture.
- Patient has received surgical intervention for his injury.
- A medical condition that would affect safety of injection (e.g. peripheral vascular disease, use of anticoagulant medication)
- Inability to give informed consent.
- Participation in other concomitant treatment programs.
- Patient has already one side included in this study.
- Patient does not wish, for whatever reason, to undergo one of the two treatments.
- Allergy for lidocain.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Our primary outcome measurement is the VISA-A score. This measures pain,<br /><br>function and activity level. It is validated en reliable for the chronic<br /><br>Achilles tendinopathy.</p><br>